Early Release – Monkeypox Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil – Volume 28, Number 11—November 2022 – Emerging Infectious Diseases journal – CDC

Monkeypox Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil

Fonte: Early Release – Monkeypox Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil – Volume 28, Number 11—November 2022 – Emerging Infectious Diseases journal – CDC

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 | NEJM

Fonte: Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 | NEJM

Nenhum dos três medicamentos avaliados evitou a ocorrência de uma visita ao pronto-socorro, hospitalização ou morte associada à Covid-19. (Financiado pela Parsemus Foundation e outros; número COVID-OUT ClinicalTrials.gov, NCT04510194. abre em uma nova guia.)

 

Mais uma estaca no “tratamento precoce”

Effect of Early Treatment with Ivermectin among Patients with Covid-19 | NEJM

Original Article from The New England Journal of Medicine — Effect of Early Treatment with Ivermectin among Patients with Covid-19

Fonte: Effect of Early Treatment with Ivermectin among Patients with Covid-19 | NEJM

 

Então, nã funciona mesmo. O mais importante do trabalho desse grupo brasileiro, além de seu n e do rigor do desenho, é que ele conta com defensores apaixonados da Ivermectina no grupo de estudo. A conclusão é inequívoca ao meu ver.

Rivaroxabana após hospitalização por covid-19: estudo MICHELLE

O ensaio clínico aberto e randomizado mostra melhores resultados com uma dose baixa de anticoagulante oral de ação direta em pacientes com alto risco de TEV e baixo risco de sangramento.

Fonte: Rivaroxabana após hospitalização por covid-19: estudo MICHELLE

Aqui o link para a publicação do Lancet

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02392-8/fulltext

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM

Original Article from The New England Journal of Medicine — Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Fonte: Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM

 Resultados modestos. Mas é um passo adiante

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021


Fonte: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

O gráfico fala por si. Não era só a coronavac afinal…

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis | NEJM

Original Article from The New England Journal of Medicine — Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Fonte: Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis | NEJM

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile | NEJM


Original Article from The New England Journal of Medicine — Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Fonte: Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile | NEJM

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia | NEJM

Original Article from The New England Journal of Medicine — Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Fonte: Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia | NEJM

 

A integra do artigo da NEJM do post anterior